Time to abandon CAR-T monotherapy for solid tumors

In recent decades, chimeric antigen receptor T (CAR-T) cell therapy has achieved dramatic success in patients with hematological malignancies. However, CAR-T cell therapy failed to effectively treat solid tumors as a monotherapy. By summarizing the challenges of CAR-T cell monotherapy for solid tumo...

Full description

Saved in:
Bibliographic Details
Published in:Biochimica et biophysica acta. Reviews on cancer 2023-07, Vol.1878 (4), p.188930-188930, Article 188930
Main Authors: Yin, Limei, Wan, Zhengwei, Sun, Ping, Shuai, Ping, Liu, Yuping
Format: Article
Language:English
Subjects:
CAR-T
Combined therapy
Immunotherapy
Solid tumor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In recent decades, chimeric antigen receptor T (CAR-T) cell therapy has achieved dramatic success in patients with hematological malignancies. However, CAR-T cell therapy failed to effectively treat solid tumors as a monotherapy. By summarizing the challenges of CAR-T cell monotherapy for solid tumors and analyzing the underlying mechanisms of combinatorial strategies to counteract these hurdles, we found that complementary therapeutics are needed to improve the scant and transient responses of CAR-T cell monotherapy in solid tumors. Further data, especially data from multicenter clinical trials regarding efficacy, toxicity, and predictive biomarkers are required before the CAR-T combination therapy can be translated into clinical settings. [Display omitted]
ISSN:0304-419X
1879-2561
DOI:10.1016/j.bbcan.2023.188930